Glycated Albumin Assay Market - Size, Share, Outlook, and Forecast till 2026

Glycation is a non-enzymatic bonding of a sugar molecule to a protein or lipid molecule without enzymatic regulation. Glycated proteins are used as biomarkers to determine the degree of glycemia in individuals with diabetes or prediabetes. The glycated albumin assay is an automated enzyme method. Measurement of the amount of the glycation reaction resulting from the combination of glucose with free amino groups in proteins present in the blood is used to monitor the level of glucose that has generally been present in body fluids over a preceding period. The glycated albumin assay may be used as a marker of glycemic control in diabetes and reflects glycemic control over the previous 2 to 4 weeks.

Get Sample copy of research report: https://www.worldwidemarketreports.com/sample/197636

Increasing number of population suffering from diabetes is a major factor driving growth of the glycated albumin assay market. According to the World Health Organization (WHO), the global prevalence of diabetes among adults over 18 years of age has increased from 4.7% in 1980 to 8.5% in 2014. The glycated albumin (GA) reflects short-term glycemia, which is measured by a standardized enzymatic methodology. Increasing adoption of glycated albumin assay for detection of diabetes mellitus, owing to its easy and fast to perform method is driving growth of the glycated albumin assay market.

Get Best Discount on Research Report: https://www.worldwidemarketreports.com/discount/197636

Key Developments of Glycated Albumin Assay Market

Market players are engaged in developing advanced method for early diagnosis and treatment of diabetes. For instance, EKF Diagnostics, the global diagnostics company, announced introduction of new diabetic biomarker test that provides a 2-3 week indicator of average blood glucose. The Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor test closes the information gap between daily blood glucose testing and the 2-3 month HbA1c reading.

Furthermore, according to a new study conducted by Wake Forest Baptist Medical Center, the gold standard long-term glucose monitoring test for patients with diabetes proved to be of limited value in dialysis patients. American Diabetes Association has deemed the HbA1c test an effective tool for diagnosing diabetes, physicians recently determined that the HbA1c is not as useful for managing patients with diabetes and advanced kidney failure. Therefore, alternative test such as the glycated albumin or GA assay, appears to be far more effective in this setting. Key players operating in glycated albumin assay market include Asahi Kasei Pharma, DIAZYME, Abnova, LifeSpan, Exocell, BSBE, Medical system, Maccura, Leadman, Simes Sikma, and Ningbo Purebio.

About WMR
Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:
Mr. Shah
Worldwide Market Reports
1001 4th Ave,
#3200
Seattle, WA 98154,
U.S
Tel: +1 415 871 0703

This release was published on openPR.